BRIEF-Aptose provides update on FDA clinical hold of APTO-253
Oct 13 (Reuters) - Aptose Biosciences Inc :
* Aptose provides update on FDA clinical hold of APTO-253
* Aptose biosciences-FDA response focused exclusively on request to provide with complete CMC information on final GMP drug substance and drug product intended for clinic
* Generation of additional data requested by FDA is underway, and once available data will be submitted for FDA review Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.